vs
Side-by-side financial comparison of Dianthus Therapeutics, Inc. (DNTH) and Nakamoto Inc. (NAKA). Click either name above to swap in a different company.
Nakamoto Inc. is the larger business by last-quarter revenue ($444.9K vs $284.0K, roughly 1.6× Dianthus Therapeutics, Inc.). Nakamoto Inc. runs the higher net margin — 8374.2% vs -22687.3%, a 31061.5% gap on every dollar of revenue. On growth, Nakamoto Inc. posted the faster year-over-year revenue change (-26.3% vs -78.6%). Over the past eight quarters, Nakamoto Inc.'s revenue compounded faster (-26.7% CAGR vs -44.6%).
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
DNTH vs NAKA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0K | $444.9K |
| Net Profit | $-64.4M | $37.3M |
| Gross Margin | — | — |
| Operating Margin | -24486.3% | -41198.2% |
| Net Margin | -22687.3% | 8374.2% |
| Revenue YoY | -78.6% | -26.3% |
| Net Profit YoY | -126.6% | 3820.2% |
| EPS (diluted) | $-1.53 | $0.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0K | $444.9K | ||
| Q3 25 | $396.0K | $388.2K | ||
| Q2 25 | — | $408.5K | ||
| Q1 25 | $1.2M | $579.7K | ||
| Q4 24 | $1.3M | $603.9K | ||
| Q3 24 | $2.2M | $647.9K | ||
| Q2 24 | $1.9M | $639.1K | ||
| Q1 24 | $874.0K | $829.0K |
| Q4 25 | $-64.4M | $37.3M | ||
| Q3 25 | $-36.8M | $-86.0M | ||
| Q2 25 | — | $-2.4M | ||
| Q1 25 | $-29.5M | $-1.0M | ||
| Q4 24 | $-28.4M | $-1.0M | ||
| Q3 24 | $-25.2M | $-1.0M | ||
| Q2 24 | $-17.6M | $-1.3M | ||
| Q1 24 | $-13.7M | $-282.3K |
| Q4 25 | -24486.3% | -41198.2% | ||
| Q3 25 | -10173.7% | -2680.4% | ||
| Q2 25 | — | -585.4% | ||
| Q1 25 | -2852.7% | -179.7% | ||
| Q4 24 | -2406.9% | -169.3% | ||
| Q3 24 | -1376.6% | -162.0% | ||
| Q2 24 | -1191.8% | -162.3% | ||
| Q1 24 | -2041.6% | -28.6% |
| Q4 25 | -22687.3% | 8374.2% | ||
| Q3 25 | -9284.1% | -22162.2% | ||
| Q2 25 | — | -590.9% | ||
| Q1 25 | -2537.5% | -179.1% | ||
| Q4 24 | -2144.8% | -165.8% | ||
| Q3 24 | -1159.0% | -156.5% | ||
| Q2 24 | -945.1% | -206.5% | ||
| Q1 24 | -1573.0% | -34.1% |
| Q4 25 | $-1.53 | $0.68 | ||
| Q3 25 | $-0.97 | $-0.42 | ||
| Q2 25 | — | $-0.35 | ||
| Q1 25 | $-0.82 | $-0.17 | ||
| Q4 24 | $-0.76 | $-0.18 | ||
| Q3 24 | $-0.74 | $-0.17 | ||
| Q2 24 | $-0.51 | $-0.26 | ||
| Q1 24 | $-0.54 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $404.3M | $22.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $493.4M | $514.3M |
| Total Assets | $530.9M | $730.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $404.3M | $22.6M | ||
| Q3 25 | $402.6M | $24.2M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | $263.2M | $1.1M | ||
| Q4 24 | $275.2M | $2.3M | ||
| Q3 24 | $281.1M | $3.6M | ||
| Q2 24 | $360.7M | $4.7M | ||
| Q1 24 | $377.0M | $287.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.4K | ||
| Q4 24 | — | $148.8K | ||
| Q3 24 | — | $205.6K | ||
| Q2 24 | — | $254.7K | ||
| Q1 24 | — | $710.0K |
| Q4 25 | $493.4M | $514.3M | ||
| Q3 25 | $546.5M | $477.6M | ||
| Q2 25 | — | $9.0M | ||
| Q1 25 | $328.6M | $1.5M | ||
| Q4 24 | $352.5M | $2.6M | ||
| Q3 24 | $337.9M | $3.5M | ||
| Q2 24 | $358.2M | $4.4M | ||
| Q1 24 | $372.7M | $-383.1K |
| Q4 25 | $530.9M | $730.6M | ||
| Q3 25 | $577.4M | $692.4M | ||
| Q2 25 | — | $9.9M | ||
| Q1 25 | $348.6M | $2.6M | ||
| Q4 24 | $374.0M | $3.7M | ||
| Q3 24 | $354.2M | $4.3M | ||
| Q2 24 | $369.0M | $5.5M | ||
| Q1 24 | $382.5M | $799.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.06× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-47.0M | $-23.5M |
| Free Cash FlowOCF − Capex | $-47.1M | — |
| FCF MarginFCF / Revenue | -16591.9% | — |
| Capex IntensityCapex / Revenue | 48.6% | — |
| Cash ConversionOCF / Net Profit | — | -0.63× |
| TTM Free Cash FlowTrailing 4 quarters | $-132.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-47.0M | $-23.5M | ||
| Q3 25 | $-30.6M | $-13.2M | ||
| Q2 25 | — | $-1.9M | ||
| Q1 25 | $-27.6M | $-865.1K | ||
| Q4 24 | $-27.4M | $-3.1M | ||
| Q3 24 | $-21.3M | $-1.0M | ||
| Q2 24 | $-14.5M | $-913.5K | ||
| Q1 24 | $-14.9M | $-213.4K |
| Q4 25 | $-47.1M | — | ||
| Q3 25 | $-30.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-27.5M | $-3.1M | ||
| Q3 24 | $-21.3M | $-1.0M | ||
| Q2 24 | $-14.5M | — | ||
| Q1 24 | $-15.0M | $-224.6K |
| Q4 25 | -16591.9% | — | ||
| Q3 25 | -7717.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -2377.8% | — | ||
| Q4 24 | -2072.0% | -511.2% | ||
| Q3 24 | -980.3% | -161.7% | ||
| Q2 24 | -780.7% | — | ||
| Q1 24 | -1713.2% | -27.1% |
| Q4 25 | 48.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 2.3% | 2.2% | ||
| Q3 24 | 1.2% | 0.3% | ||
| Q2 24 | 0.9% | 0.0% | ||
| Q1 24 | 3.7% | 1.3% |
| Q4 25 | — | -0.63× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
